Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs
NCT06708611 · Sarfez Pharmaceuticals, Inc. · PHASE4 · withdrawn · last registry update 2026-04-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment issues” | – | Registry record, Sarfez Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-28Also stopped (withdrawn): Sarfez Pharmaceuticals, Inc., Extended Release Torsemide Tablets + Immedate Release Torsemide Tablets (NCT06995144)
- 2026-09-22Also stopped (withdrawn): Sarfez Pharmaceuticals, Inc., Combination Product: FDC of spironolactone and ER torsemide + Combination Product: Stabilized doses of loop diuretic and finerenone (NCT07223502)
- 2026-07-30Phase 3 first posted: University Hospital, Montpellier, Acetazolamide + Furosemide (NCT07737964)
- 2026-07-14Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Furosemide (plus potassium chloride) + Placebo (plus placebo electrolyte solution) (NCT05898022)
- 2026-07-06Phase 3 first posted: Beni-Suef University, Dapagliflozin (NCT07684326)
- 2026-06-15Results posted on the registry: SQ Innovation, Inc., Furosemide Injection Solution for subcutaneous administration (80 mg) + Furosemide Injection, USP (NCT04384653)
- 2026-06-09Also stopped (withdrawn): University Hospital, Limoges, Bumetanide + Placebo (NCT02947880)
- 2026-05-29Results posted on the registry: Reprieve Cardiovascular, Inc, Diuretic (NCT05174312)
- 2026-05-19Phase 3 first posted: University of Monastir, Hypertonic sodium chloride 10% + Sodium Chloride 0.9% (NCT07596329)
- 2026-05-08Also stopped (terminated): University of Alberta, Furosemide + Chlorthalidone (NCT05915286)
- 2026-04-27Also stopped (withdrawn): Sarfez Pharmaceuticals, Inc., Immediate release torsemide 20mg tablet + Extended release torsemide 24mg tablet (NCT06176794)
- 2026-04-24Also stopped (terminated): Sarfez Pharmaceuticals, Inc., CHF Patients: ER Torsemide 40 mg + CHF Patients: Furosemide 40 mg (NCT03509545)
- 2026-04-24Results posted on the registry: SQ Innovation, Inc., SQIN-01 (NCT04846816)
- 2026-03-13Phase 3 first posted: Hospital de Clinicas de Porto Alegre, Furosemide 40 Milligrams. + Furosemide 40 Milligrams. (NCT07469722)
- 2026-03-11Results posted on the registry: scPharmaceuticals, Inc., SCP-111 + Furosemide USP (NCT06167707)
- 2026-01-29Also stopped (withdrawn): Prisma Health-Upstate, Bumetanide, intranasal 4mg (NCT07375212)
- 2026-01-14Results posted on the registry: Mayo Clinic, Bumetanide + Furosemide (NCT06036914)
- 2026-01-13Results posted on the registry: Boehringer Ingelheim, Rosuvastatin + Digoxin (NCT05741372)
- 2026-01-09Results posted on the registry: Boehringer Ingelheim, Zongertinib + Dabigatran-etexilate (NCT06504862)
- 2025-12-08Results posted on the registry: University of Delaware, a drug against SLC12A1 (NCT05480722)
- 2025-10-31Phase 3 first posted: Sarfez Pharmaceuticals, Inc., Combination Product: FDC of spironolactone and ER torsemide + Combination Product: Stabilized doses of loop diuretic and finerenone (NCT07223502)
- 2025-10-27Results posted on the registry: Emory University, Furosemide (NCT05779943)
- 2025-10-16Results posted on the registry: Duke University, Torsemide + Furosemide (NCT03296813)
- 2025-09-16Also stopped (terminated): Rush University Medical Center, Furosemide Injection + Albumin Human (NCT04216784)
- 2025-08-08Results posted on the registry: Vrije Universiteit Brussel, Intravenous acetazolamide 500 mg OD + Intravenous bumetanide TID (NCT05411991)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision